Pre-clinical validation of an RNA-based precision oncology platform for patient-therapy alignment in a diverse set of human malignancies resistant to standard treatments
Open accessThe DOI matches its Crossref record; 84 of the 85 references it cites were found in a registry or an index.
Abstract
Predicting tumor sensitivity to antineoplastics remains an elusive challenge, with no methods demonstrating predictive power. Joint analysis of tumors—from patients with distinct malignancies who had progressed on multiple lines of therapy—and drug perturbation transcriptional profiles predicted sensitivity to 28 of 350 drugs, 26 of which (93%) were confirmed in low-passage, patient-derived xenograft (PDX) models. Drugs were prioritized based on their ability to either invert the activity of individual Master Regulator proteins, with available high-affinity inhibitors, or of the modules they comprise (Tumor-Checkpoints), based on de novo mechanism of action analysis. Of 138 PDX mice enrolled in 16 single and 18 multi-protein treatment arms, a disease control rate (DCR) of 68% and 91 %, and an objective response rate (ORR) of 12% and 17%, were achieved respectively, compared to 6% and 0% in the negative controls arm, with multi-protein drugs achieving significantly more durable responses. Thus, these approaches may effectively complement and expand current precision oncology approaches, as also illustrated by a case study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These PDX model systems are of particular value in both basic science and potentially personalized medicine research 180,183,222 as they have clinical and molecular features that are quite representative of the human disease 223,224,225,226 .”
From Osteosarcoma (2022) · cites this paper as [226]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106 · cited 1×
“Raw counts were normalized and variance stabilized by fitting the dispersion to a negative-binomial distribution as implemented in the DESeq2 R-package (RRID: SCR_000154) (64).”
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Gene Ontology: tool for the unification of biology
Ashburner, M., Ball, C. A., Blake, J. A., Botstein, D., Butler, H., Cherry, J. M., Davis, A. P., Dolinski, K., Dwight, S. S., Eppig, J. T., et al. (2000) · Nature Genetics · doi:10.1038/75556 · Cited by 43,206 · cited 1×
“…100 bootstrap iterations using an input set of candidate regulators including: (a) 1,877 transcription factors annotated in the Gene Ontology (GO) (65) “Molecular Function database” as DNA-binding transcription factor activity (GO:0003700), DNA binding (GO:0003677), Transcription regulator…”
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261 · cited 1×
“To illustrate the selection process, in Figure S3A we show the MR-based fidelity of the top 12 breast cancer cell lines identified as candidate cognate models of BLBC tumors in TCGA, as annotated by PAM50 classification (21, 22).”
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950 · cited 3×
“Cell lines were selected from a total of 97 profiled breast cancer cell lines, unbiased to receptor status or PAM50 classification, as part of a comprehensive repository that included both the Cancer Cell Line Encyclopedia (CCLE) (23) and the Genentech Cell Line Screening Initiative (gCSI) (24).”
Lehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y., & Pietenpol, J. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45014 · Cited by 5,592 · cited 1×
“…BLBC patients would be classified as luminal, several of them were claudin-low or mesenchymal like (e.g., MDAMB231, SUM159PT, BT549, CAL120), unclassifiable (e.g., BT20, HCC1395), or even ER-negative, HER2-amplified/enriched (e.g., JIMT1, HCC1954) by transcriptome-based classifications (25, 26).”
Elkablawy, M. A., Albasri, A. M., Mohammed, R. A., Hussainy, A. S., Nouh, M. M., & Alhujaily, A. S. (2016) · Saudi Medical Journal · doi:10.15537/smj.2016.2.12285 · Cited by 4,382
Greaves, M., & Maley, C. C. (2012) · Nature · doi:10.1038/nature10762 · Cited by 3,162 · cited 1×
“PDX fidelity assessment: Tumors undergo clonal evolution under various selection pressures, including available nutrients, organ-specific environment, immune editing, pharmacological treatment, and growth kinetics [34].”
BackgroundDrugBank: a knowledgebase for drugs, drug actions and drug targets
Wishart, D. S., Knox, C., Guo, A. C., Cheng, D., Shrivastava, S., Tzur, D., Gautam, B., & Hassanali, M. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkm958 · Cited by 2,861 · cited 3×
“Through the use of (a) DrugBank (69), (b) the SelleckChem database (RRID:SCR_003823), (c) published literature, and (d) publicly available information on pharmaceutical company drug development pipelines, we have curated a refined list of 180 actionable proteins representing validated targets of…”
InfluentialMargolin, A. A., Nemenman, I., Basso, K., Wiggins, C., Stolovitzky, G., Favera, R. D., & Califano, A. (2006) · BMC Bioinformatics · doi:10.1186/1471-2105-7-s1-s7 · Cited by 2,420 · cited 2×
“To support context-specific regulatory protein activity inference by VIPER, we have generated comprehensive molecular interaction networks (interactomes) using the Algorithm for the Reconstruction of Accurate Cellular Networks (ARACNe) (61, 62), although other suitable algorithms may be used.”
Self-citationMolecular principles of metastasis: a hallmark of cancer revisited
Fares, J., Fares, M. Y., Khachfe, H. H., Salhab, H. A., & Fares, Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0134-x · Cited by 2,379 · cited 1×
“…our methodology can capture longitudinal changes, such as we have shown for metastatic progression in breast cancer and neuroendocrine tumors (13, 57), histologic transformation in follicular lymphoma (15), therapy resistance in T-ALL and breast cancer (55, 58), and reprogramming of…”
Margolin, A. A., Nemenman, I. M., Basso, K., Wiggins, C. H., Stolovitzky, G. A., Favera, R. D., & Califano, A. (2006) · BMC Bioinformatics · doi:10.7916/d8g15zbp · Cited by 2,246
Self-citationElyada, E., Bolisetty, M., Laise, P., Flynn, W. F., Courtois, E. T., Burkhart, R. A., Teinor, J. A., Belleau, P., Biffi, G., Lucito, M. S., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0094 · Cited by 2,241
Self-citationMemorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)
Cheng, D. T., Mitchell, T. N., Zehir, A., Shah, R. H., Benayed, R., Syed, A., Chandramohan, R., Liu, Z. Y., Won, H. H., Scott, S. N., et al. (2015) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2014.12.006 · Cited by 2,119 · cited 2×
“Memorial Sloan Kettering IMPACT (37), a targeted next-generation sequencing panel covering 468 genes, was performed on a biopsy specimen and demonstrated a CTNNB1 hotspot mutation, TERT promoter gain of function mutation, and an NTRK3 point mutation not known to predict response to currently available TRK inhibitors.”
Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research
Hidalgo, M., Amant, F., Biankin, A. V., Budinská, E., Byrne, A. T., Caldas, C., Clarke, R. B., de Jong, S., Jonkers, J., Mælandsmo, G. M., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0001 · Cited by 1,742 · cited 1×
“…from implanted patient tumor tissue may be influenced by sundry factors—including histology, mitotic rate, and fraction of cancer stem cells (41)—while the timeline between implantation and completion of drug testing can vary greatly (e.g., 3 to 18 months in our experience), with some tumor…”
Addiction to Oncogenes--the Achilles Heal of Cancer
Weinstein, I. B. (2002) · Science · doi:10.1126/science.1073096 · Cited by 1,728 · cited 1×
“…one (oncogene addiction) aims to identify targeted therapies based on the presence of activating genetic alterations in druggable oncoproteins (3); the second (immunotherapy) is based on the discovery that specific tumor-initiated immunosuppressive programs can be abrogated by pharmacological…”
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., Yang, W., Tian, C., Miao, Z., Wang, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00572-w · Cited by 1,696
Reverse engineering of regulatory networks in human B cells
Basso, K., Margolin, A. A., Stolovitzky, G., Klein, U., Dalla-Favera, R., & Califano, A. (2005) · Nature Genetics · doi:10.1038/ng1532 · Cited by 1,404 · cited 6×
“The networks were reverse engineered by ARACNe from ≥ 100 RNASeq profiles of human cancer tissue from (a) The Cancer Genome Atlas (TCGA) and (b) for meningioma and neuroendocrine tumors, from Columbia University collected datasets (Table S8).”
InfluentialSelf-citationHerschkowitz, J. I., Simin, K., Weigman, V. J., Mikaelian, I., Usary, J., Hu, Z., Rasmussen, K. E., Jones, L. P., Assefnia, S., Chandrasekharan, S., et al. (2007) · Genome Biology · doi:10.1186/gb-2007-8-5-r76 · Cited by 1,285 · cited 1×
“…BLBC patients would be classified as luminal, several of them were claudin-low or mesenchymal like (e.g., MDAMB231, SUM159PT, BT549, CAL120), unclassifiable (e.g., BT20, HCC1395), or even ER-negative, HER2-amplified/enriched (e.g., JIMT1, HCC1954) by transcriptome-based classifications (25, 26).”
The transcriptional network for mesenchymal transformation of brain tumours
Carro, M. S., Lim, W. K., Alvarez, M. J., Bollo, R. J., Zhao, X., Snyder, E. Y., Sulman, E. P., Anne, S. L., Doetsch, F., Colman, H., et al. (2010) · Nature · doi:10.1038/nature08712 · Cited by 1,259
Self-citationLe Tourneau, C., Delord, J.-P., Gonçalves, A., Gavoille, C., Dubot, C., Isambert, N., Campone, M., Trédan, O., Massiani, M.-A., Mauborgne, C., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00188-6 · Cited by 1,137
Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma
Compagno, M., Lim, W. K., Grunn, A., Nandula, S. V., Brahmachary, M., Shen, Q., Bertoni, F., Ponzoni, M., Scandurra, M., Califano, A., et al. (2009) · Nature · doi:10.1038/nature07968 · Cited by 1,038
Self-citationAlvarez, M. J., Shen, Y., Giorgi, F. M., Lachmann, A., Ding, B. B., Ye, B. H., & Califano, A. (2016) · Nature Genetics · doi:10.1038/ng.3593 · Cited by 966 · cited 8×
“Cell line and PDX model fidelity to human tumors was assessed based on the normalized enrichment score (NES) of the top 50 patient-specific activated and inactivated MRs in differentially activate and inactive proteins in each cell line or PDX, respectively, by analytic-rank based enrichment analysis [20] (aREA: p ≤ 1…”
BackgroundMethodInfluentialSelf-citationThe great escape: tumour cell plasticity in resistance to targeted therapy
Boumahdi, S., & de Sauvage, F. J. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0044-1 · Cited by 761
Patient-derived xenografts undergo mouse-specific tumor evolution
Ben-David, U., Ha, G., Tseng, Y.-Y., Greenwald, N. F., Oh, C., Shih, J., McFarland, J. M., Wong, B., Boehm, J. S., Beroukhim, R., et al. (2017) · Nature Genetics · doi:10.1038/ng.3967 · Cited by 716
Tumor measurement in the nude mouse
Euhus, D. M., Hudd, C., Laregina, M. C., & Johnson, F. E. (1986) · Journal of Surgical Oncology · doi:10.1002/jso.2930310402 · Cited by 605 · cited 1×
“While clinical response assessments using RECIST are based on unidimensional measurements, bi-directional caliper measurements to estimate tumor volume are standard practice in mouse studies, but are prone to significant interobserver variability (49, 50).”
Zhang, X., Claerhout, S., Prat, A., Dobrolecki, L. E., Petrovic, I., Lai, Q., Landis, M. D., Wiechmann, L., Schiff, R., Giuliano, M., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4081 · Cited by 481
Genomic correlates of response to immune checkpoint blockade
Keenan, T. E., Burke, K. P., & Van Allen, E. M. (2019) · Nature Medicine · doi:10.1038/s41591-019-0382-x · Cited by 448
Meric-Bernstam, F., Brusco, L., Shaw, K., Horombe, C., Kopetz, S., Davies, M. A., Routbort, M., Piha-Paul, S. A., Janku, F., Ueno, N., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.4165 · Cited by 424 · cited 1×
“mostly transitory, from targeted therapy [7].”
Limits to Personalized Cancer Medicine
Tannock, I. F., & Hickman, J. A. (2016) · New England Journal of Medicine · doi:10.1056/nejmsb1607705 · Cited by 415
Lachmann, A., Giorgi, F. M., Lopez, G., & Califano, A. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw216 · Cited by 407
Self-citationMeasuring Response in Solid Tumors: Unidimensional Versus Bidimensional Measurement
James, K., Eisenhauer, E., Christian, M., Terenziani, M., Vena, D., Muldal, A., & Therasse, P. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.6.523 · Cited by 401 · cited 2×
“When considering the various factors that can contribute to variability in tumor measurements, our definition of progressive disease (100% tumor volume increase relative to baseline) remains within reasonable margins of error (± 1–2 mm) and aligns with volumetric definitions of progression (51–53).”
Zou, M., Toivanen, R., Mitrofanova, A., Floch, N., Hayati, S., Sun, Y., Le Magnen, C., Chester, D., Mostaghel, E. A., Califano, A., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1174 · Cited by 386 · cited 1×
“…have shown for metastatic progression in breast cancer and neuroendocrine tumors (13, 57), histologic transformation in follicular lymphoma (15), therapy resistance in T-ALL and breast cancer (55, 58), and reprogramming of castrate-resistant prostate adenocarcinoma to a neuroendocrine state (59).”
Self-citationGeneration of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice
Kim, M. P., Evans, D. B., Wang, H., Abbruzzese, J. L., Fleming, J. B., & Gallick, G. E. (2009) · Nature Protocols · doi:10.1038/nprot.2009.171 · Cited by 380
Elucidating Compound Mechanism of Action by Network Perturbation Analysis
Woo, J. H., Shimoni, Y., Yang, W. S., Subramaniam, P., Iyer, A., Nicoletti, P., Rodríguez Martínez, M., López, G., Mattioli, M., Realubit, R., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.056 · Cited by 351 · cited 1×
“We used the highest sublethal drug concentration to reveal signatures optimally reflective of the drug’s MoA rather than non-specific effector proteins in stress or death pathways (27, 28).”
Self-citationSingle-cell protein activity analysis identifies recurrence-associated renal tumor macrophages
Obradovic, A., Chowdhury, N., Haake, S. M., Ager, C., Wang, V., Vlahos, L., Guo, X. V., Aggen, D. H., Rathmell, W. K., Jonasch, E., et al. (2021) · Cell · doi:10.1016/j.cell.2021.04.038 · Cited by 349 · cited 2×
“…to measure protein activity in single cells, comparing favorably with antibody-based measurements and recapitulating bulk measurements (17, 60), thus supporting drug predictions for specific tumor subpopulations (bioRxiv 2022.02.28.482410), including immunosuppressive, non-transformed…”
InfluentialSelf-citationAytes, A., Mitrofanova, A., Lefebvre, C., Alvarez, M. J., Castillo-Martin, M., Zheng, T., Eastham, J. A., Gopalan, A., Pienta, K. J., Shen, M. M., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.03.017 · Cited by 324 · cited 1×
“About 30% of MR proteins were shown to represent tumor-essential, non-oncogene dependencies, either individually (8) or in combination (10, 11).”
Self-citationA community computational challenge to predict the activity of pairs of compounds
Community, N.-D., Bansal, M., Yang, J., Karan, C., Menden, M. P., Costello, J. C., Tang, H., Xiao, G., Li, Y., Allen, J., et al. (2014) · Nature Biotechnology · doi:10.1038/nbt.3052 · Cited by 321 · cited 2×
“We used the highest sublethal drug concentration to reveal signatures optimally reflective of the drug’s MoA rather than non-specific effector proteins in stress or death pathways (27, 28).”
Self-citationReproducible pharmacogenomic profiling of cancer cell line panels
Haverty, P. M., Lin, E., Tan, J., Yu, Y., Lam, B., Lianoglou, S., Neve, R. M., Martin, S., Settleman, J., Yauch, R. L., et al. (2016) · Nature · doi:10.1038/nature17987 · Cited by 289 · cited 2×
“Cell lines were selected from a total of 97 profiled breast cancer cell lines, unbiased to receptor status or PAM50 classification, as part of a comprehensive repository that included both the Cancer Cell Line Encyclopedia (CCLE) (23) and the Genentech Cell Line Screening Initiative (gCSI) (24).”
Fichtner, I., Rolff, J., Soong, R., Hoffmann, J., Hammer, S., Sommer, A., Becker, M., & Merk, J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0138 · Cited by 286
The Genotype-Tissue Expression (GTEx) project
Lonsdale, J., Thomas, J., Salvatore, M., Phillips, R., Lo, E., Shad, S., Hasz, R., Walters, G., Garcia, F., Young, N., et al. (2013) · Nature Genetics · doi:10.1038/ng.2653 · Cited by 263 · cited 1×
“While organ-matched normal tissue expression profiles, such as those available from the Genotype-Tissue Expression (GTEx) resource (66), and cohort-matched tumor and tumor-adjacent profiles were considered, such references would potentially over-emphasize proliferative and cell cycle signals and…”
Direct Reversal of Glucocorticoid Resistance by AKT Inhibition in Acute Lymphoblastic Leukemia
Piovan, E., Yu, J., Tosello, V., Herranz, D., Ambesi-Impiombato, A., Da Silva, A. C., Sanchez-Martin, M., Perez-Garcia, A., Rigo, I., Castillo, M., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.10.022 · Cited by 256 · cited 2×
“…have shown for metastatic progression in breast cancer and neuroendocrine tumors (13, 57), histologic transformation in follicular lymphoma (15), therapy resistance in T-ALL and breast cancer (55, 58), and reprogramming of castrate-resistant prostate adenocarcinoma to a neuroendocrine state (59).”
Self-citationVaubel, R. A., Tian, S., Remonde, D., Schroeder, M. A., Mladek, A. C., Kitange, G. J., Caron, A., Kollmeyer, T. M., Grove, R., Peng, S., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0909 · Cited by 227 · cited 1×
“Consistent with the experience of other groups, less than half of attempted PDXs could be established (Table S1), and there was obvious tumor type bias (42–48).”
Self-citationAn expanded universe of cancer targets
Hahn, W. C., Bader, J. S., Braun, T. P., Califano, A., Clemons, P. A., Druker, B. J., Ewald, A. J., Fu, H., Jagu, S., Kemp, C. J., et al. (2021) · Cell · doi:10.1016/j.cell.2021.02.020 · Cited by 213
Self-citationAlvarez, M. J., Subramaniam, P. S., Tang, L. H., Grunn, A., Aburi, M., Rieckhof, G., Komissarova, E. V., Hagan, E. A., Bodei, L., Clemons, P. A., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0138-4 · Cited by 210 · cited 10×
“In that study, OncoTreat identified entinostat, a class I histone deacetylase inhibitor, among 105 profiled drugs, as a highly effective TCM-inverter drug (13), leading to a clinical trial that is currently accruing patients (NCT03211988).”
InfluentialSelf-citationThe recurrent architecture of tumour initiation, progression and drug sensitivity
Califano, A., & Alvarez, M. J. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.124 · Cited by 204 · cited 5×
“About 30% of MR proteins were shown to represent tumor-essential, non-oncogene dependencies, either individually (8) or in combination (10, 11).”
InfluentialSelf-citationA Validated Tumorgraft Model Reveals Activity of Dovitinib Against Renal Cell Carcinoma
Sivanand, S., Peña-Llopis, S., Zhao, H., Kucejova, B., Spence, P., Pavia-Jimenez, A., Yamasaki, T., McBride, D. J., Gillen, J., Wolff, N. C., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003643 · Cited by 193
Uniform genomic data analysis in the NCI Genomic Data Commons
Zhang, Z., Hernandez, K. M., Savage, J. H., Li, S., Miller, D. P., Agrawal, S., Ortuño, F. M., Staudt, L. M., Heath, A. P., & Grossman, R. L. (2021) · Nature Communications · doi:10.1038/s41467-021-21254-9 · Cited by 189 · cited 1×
“TCGA RNASeq level 3 data were downloaded from NCI Genomics Data Commons (63).”
Chen, J. C., Alvarez, M. J., Talos, F., Dhruv, H., Rieckhof, G. E., Iyer, A., Diefes, K. L., Aldape, K., Berens, M., Shen, M. M., et al. (2014) · Cell · doi:10.1016/j.cell.2014.09.021 · Cited by 188
Self-citationDifferentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancer
Risom, T., Langer, E. M., Chapman, M. P., Rantala, J., Fields, A. J., Boniface, C., Alvarez, M. J., Kendsersky, N. D., Pelz, C. R., Johnson-Camacho, K., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05729-w · Cited by 174 · cited 1×
“…have shown for metastatic progression in breast cancer and neuroendocrine tumors (13, 57), histologic transformation in follicular lymphoma (15), therapy resistance in T-ALL and breast cancer (55, 58), and reprogramming of castrate-resistant prostate adenocarcinoma to a neuroendocrine state (59).”
Self-citationRajbhandari, P., Lopez, G., Capdevila, C., Salvatori, B., Yu, J., Rodriguez-Barrueco, R., Martinez, D., Yarmarkovich, M., Weichert-Leahey, N., Abraham, B. J., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0861 · Cited by 170 · cited 2×
“Indeed, genetic (10–12) or pharmacological (13–15) inhibition of MR proteins has been shown effective in inverting the activity of TCM MRs, resulting in abrogation of tumor viability in vitro and in vivo.”
Self-citationTrends in the global immuno-oncology landscape
Tang, J., Pearce, L., O’Donnell-Tormey, J., & Hubbard-Lucey, V. M. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.167 · Cited by 150 · cited 1×
“…activating genetic alterations in druggable oncoproteins (3); the second (immunotherapy) is based on the discovery that specific tumor-initiated immunosuppressive programs can be abrogated by pharmacological targeting of immune checkpoints or by sensitizing the immune system to tumor antigens (4).”
Dix, D. B., Seibel, N. L., Chi, Y.-Y., Khanna, G., Gratias, E. J., Anderson, J. R., Mullen, E. A., Geller, J. I., Kalapurakal, J. A., Paulino, A. C., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.1931 · Cited by 137 · cited 1×
“…WT1 and β -catenin expression by immunohistochemistry), the patient was treated with 10 neoadjuvant cycles of a “Wilms’ tumor like-regimen”, including five cycles of vincristine/irinotecan, four cycles of vincristine/dactinomycin/ doxorubicin, and one cycle of cyclophosphamide/topotecan (38, 39).”
A modular master regulator landscape controls cancer transcriptional identity
Paull, E. O., Aytes, A., Jones, S. J., Subramaniam, P. S., Giorgi, F. M., Douglass, E. F., Tagore, S., Chu, B., Vasciaveo, A., Zheng, S., et al. (2021) · Cell · doi:10.1016/j.cell.2020.11.045 · Cited by 135
Self-citationWhen Progressive Disease Does Not Mean Treatment Failure: Reconsidering the Criteria for Progression
Oxnard, G. R., Morris, M. J., Hodi, F. S., Baker, L. H., Kris, M. G., Venook, A. P., & Schwartz, L. H. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs353 · Cited by 129 · cited 1×
“When considering the various factors that can contribute to variability in tumor measurements, our definition of progressive disease (100% tumor volume increase relative to baseline) remains within reasonable margins of error (± 1–2 mm) and aligns with volumetric definitions of progression (51–53).”
Walsh, L. A., Alvarez, M. J., Sabio, E. Y., Reyngold, M., Makarov, V., Mukherjee, S., Lee, K.-W., Desrichard, A., Turcan, Ş., Dalin, M. G., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.07.052 · Cited by 120
Self-citationDing, H., Douglass, E. F., Sonabend, A. M., Mela, A., Bose, S., Gonzalez, C., Canoll, P. D., Sims, P. A., Alvarez, M. J., & Califano, A. (2018) · Nature Communications · doi:10.1038/s41467-018-03843-3 · Cited by 117 · cited 3×
“…to measure protein activity in single cells, comparing favorably with antibody-based measurements and recapitulating bulk measurements (17, 60), thus supporting drug predictions for specific tumor subpopulations (bioRxiv 2022.02.28.482410), including immunosuppressive, non-transformed…”
InfluentialSelf-citationRodriguez-Barrueco, R., Yu, J., Saucedo-Cuevas, L. P., Olivan, M., Llobet-Navas, D., Putcha, P., Castro, V., Murga-Penas, E. M., Collazo-Lorduy, A., Castillo-Martin, M., et al. (2015) · Genes & Development · doi:10.1101/gad.262642.115 · Cited by 110
Self-citationPLATE-Seq for genome-wide regulatory network analysis of high-throughput screens
Bush, E. C., Ray, F., Alvarez, M. J., Realubit, R., Li, H., Karan, C., Califano, A., & Sims, P. A. (2017) · Nature Communications · doi:10.1038/s41467-017-00136-z · Cited by 107 · cited 3×
“Multiplexed, low depth (1M to 2M reads) RNASeq profiles were generated using 96-well plates via the PLATE-Seq technology, using fully automated microfluidics for increased throughput and reproducibility [29].”
InfluentialSelf-citationDrug and disease signature integration identifies synergistic combinations in glioblastoma
Stathias, V., Jermakowicz, A. M., Maloof, M. E., Forlin, M., Walters, W., Suter, R. K., Durante, M. A., Williams, S. L., Harbour, J. W., Volmar, C.-H., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07659-z · Cited by 99 · cited 2×
“Compared to other related efforts, such as SynergySeq (19), which predict drug sensitivity based on the greatest divergence between drug perturbation and tumor transcriptomic signatures, our methods capitalize on robust network-based assessment of functional protein activity and are built on a…”
Daw, N. C., Chi, Y., Kalapurakal, J. A., Kim, Y., Hoffer, F. A., Geller, J. I., Perlman, E. J., Ehrlich, P. F., Mullen, E. A., Warwick, A. B., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01265 · Cited by 94 · cited 1×
“…WT1 and β -catenin expression by immunohistochemistry), the patient was treated with 10 neoadjuvant cycles of a “Wilms’ tumor like-regimen”, including five cycles of vincristine/irinotecan, four cycles of vincristine/dactinomycin/ doxorubicin, and one cycle of cyclophosphamide/topotecan (38, 39).”
Nested Stromal Epithelial Tumor of the Liver
Heerema‐McKenney, A., Leuschner, I., Smith, N., Sennesh, J. D., & Finegold, M. J. (2004) · The American Journal of Surgical Pathology · doi:10.1097/01.pas.0000147398.03015.9e · Cited by 80 · cited 1×
“While localized disease is often effectively cured with surgery, recurrent and de novo metastatic disease demonstrates chemotherapy resistance and there are no proven therapeutic options (33–36).”
Zeleke, T. Z., Pan, Q., Chiuzan, C., Onishi, M., Li, Y., Tan, H., Alvarez, M. J., Honan, E., Yang, M., Chia, P. L., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00489-5 · Cited by 78 · cited 6×
“Yet, our study and some initial clinical confirmations (56) suggest that these tests may represent a novel PCM option for mechanism-based prioritization of existing, clinically relevant drugs that is not currently available to cancer patients and, thus, potentially complement successful approaches…”
InfluentialSelf-citationSubcutaneous tumor volume measurement in the awake, manually restrained mouse using MRI
Kersemans, V., Cornelissen, B. T., Allen, P. D., Beech, J. S., & Smart, S. (2012) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.23829 · Cited by 72 · cited 1×
“While clinical response assessments using RECIST are based on unidimensional measurements, bi-directional caliper measurements to estimate tumor volume are standard practice in mouse studies, but are prone to significant interobserver variability (49, 50).”
Douglass, E. F., Allaway, R. J., Szalai, B., Wang, W., Tian, T., Fernández-Torras, A., Realubit, R., Karan, C., Zheng, S., Pessia, A., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100492 · Cited by 68
Self-citationWang, V. E., Xue, J. Y., Frederick, D. T., Cao, Y., Lin, E., Wilson, C., Urisman, A., Carbone, D. P., Flaherty, K. T., Bernards, R., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2779 · Cited by 54 · cited 1×
“Indeed, aberrant protein activity can result not only from activating mutations in the encoding gene but also by mutations and signals in upstream pathways (7), as well as by autocrine, paracrine, and endocrine signals (18).”
Bisikirska, B., Bansal, M., Shen, Y., Teruya-Feldstein, J., Chaganti, R., & Califano, A. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-0828 · Cited by 49 · cited 4×
“Indeed, we have previously reported on several MR-based insights in lymphoma and leukemia (15, 55), including OncoTreat-based prediction of drug synergy (27), and these malignancies will constitute a focus of future studies.”
InfluentialSelf-citationAssmann, G., Kappler, R., Zeindl‐Eberhart, E., Schmid, I., Häberle, B., Graeb, C., Jung, A., & Müller‐Höcker, J. (2012) · Human Pathology · doi:10.1016/j.humpath.2012.03.018 · Cited by 46
OncoLoop: A Network-Based Precision Cancer Medicine Framework
Vasciaveo, A., Arriaga, J. M., de Almeida, F. N., Zou, M., Douglass, E. F., Picech, F., Shibata, M., Rodríguez-Calero, A., de Brot, S., Mitrofanova, A., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0342 · Cited by 42 · cited 1×
“Additionally, prior to commencing therapeutic testing, we assessed both model fidelity and patient/PDX conservation of drug prediction, as proposed in (31).”
Self-citationInterval approach to assessing antitumor activity for tumor xenograft studies
Wu, J., & Houghton, P. J. (2009) · Pharmaceutical Statistics · doi:10.1002/pst.369 · Cited by 33
Patient-Derived Orthotopic Xenograft (PDOX) Mouse Models of Primary and Recurrent Meningioma
Zhang, H., Qi, L., Du, Y., Huang, L. F., Braun, F., Kogiso, M., Zhao, Y., Li, C., Lindsay, H., Zhao, S., et al. (2020) · Cancers · doi:10.3390/cancers12061478 · Cited by 31
Two-sample tests for growth curves under dependent right censoring
Vardi, Y., Ying, Z., & Zhang, C.-H. (2001) · Biometrika · doi:10.1093/biomet/88.4.949 · Cited by 28
Calcifying nested stromal-epithelial tumor (CNSET) of the liver in Beckwith-Wiedemann syndrome
Khoshnam, N., Robinson, H. B., Clay, M. R., Schaffer, L. R., Gillespie, S. E., & Shehata, B. M. (2016) · European Journal of Medical Genetics · doi:10.1016/j.ejmg.2016.12.001 · Cited by 25
Coutinho, D. F., Mundi, P. S., Marks, L. J., Burke, C., Ortiz, M. V., Diolaiti, D., Bird, L., Vallance, K., Ibáñez, G., You, D., et al. (2022) · Med · doi:10.1016/j.medj.2022.09.002 · Cited by 24 · cited 1×
“When cancer type specific networks are not available, we use an integrated network approach as implemented in metaVIPER (60, 68).”
Self-citationCalcifying Nested Stromal-Epithelial Tumor of the Liver: An Update and Literature Review
Benedict, M., & Zhang, X. (2018) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2017-0346-rs · Cited by 22 · cited 1×
“Calcifying Nested Stromal Epithelial Tumor (CNSET) is an exceptionally uncommon primary hepatic tumor that occurs in children and young adults, with only about 40 cases reported in the literature (32).”
Laise, P., Turunen, M. M., Garcia, A. C., Tomassoni, L., Maurer, H. C., Elyada, E., Schmierer, B., Worley, J., Kesner, J. S., Tan, X., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.10.27.357269 · Cited by 21
Self-citationTranslational Strategies for Repotrectinib in Neuroblastoma
O’Donohue, T. J., Ibáñez, G., Coutinho, D. F., Mauguen, A., Siddiquee, A. H., Rosales, N., Calder, P., Ndengu, A. A., You, D., Long, M. M., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0126 · Cited by 17
Self-citationReply to ‘H-STS, L-STS and KRJ-I are not authentic GEPNET cell lines’
Alvarez, M. J., Yan, P., Alpaugh, M. L., Bowden, M., Sicińska, E., Zhou, C. W., Karan, C., Realubit, R. B., Mundi, P. S., Grunn, A., et al. (2019) · Nature Genetics · doi:10.1038/s41588-019-0509-5 · Cited by 15 · cited 1×
“As such, we assess model fidelity to a human tumor based on TCM MR enrichment (i.e., top 25 ↑ +25 ↓ ) of the human tumor in differentially active and inactive proteins in the model, respectively (OncoMatch analysis (13, 20) (bioRxiv 2019.677435), threshold Bonferroni p ≤ 10 −10 , see Methods).”
InfluentialSelf-citationTehseen, S., Rapkin, L. B., Schemankewitz, E., Magliocca, J. F., & Romero, R. (2017) · Pediatric Transplantation · doi:10.1111/petr.13000 · Cited by 11 · cited 1×
“While localized disease is often effectively cured with surgery, recurrent and de novo metastatic disease demonstrates chemotherapy resistance and there are no proven therapeutic options (33–36).”
Na, Y.-S., Ryu, M., Park, Y. S., Lee, C., Lee, J., Park, Y., Park, J. M., Ma, J., & Kang, Y. (2020) · Scientific Reports · doi:10.1038/s41598-020-64552-w · Cited by 11
Single-cell based elucidation of molecularly-distinct glioblastoma states and drug sensitivityPreprint
Ding, H., Burgenske, D. M., Zhao, W., Subramaniam, P. S., Bakken, K. K., He, L., Alvarez, M. J., Laise, P., Paull, E., Spinazzi, E. F., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/675439 · Cited by 8
Self-citation
Cited by
Beird, H. C., Bielack, S. S., Flanagan, A. M., Gill, J., Heymann, D., Janeway, K. A., Livingston, J. A., Roberts, R. D., Strauss, S. J., & Gorlick, R. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00409-y · Cited by 660
NetBID2 provides comprehensive hidden driver analysis
Dong, X., Ding, L., Thrasher, A., Wang, X., Liu, J., Pan, Q., Rash, J., Dhungana, Y., Yang, X., Risch, I., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38335-6 · Cited by 37
PDX models for functional precision oncology and discovery science
Blanchard, Z., Brown, E. A., Ghazaryan, A., & Welm, A. L. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00779-3 · Cited by 71
“As an example, to identify vulnerabilities across a range of cancer types, the OncoTarget and OncoTreat 160 platforms were developed, which use integrated PDX gene expression and protein activity prediction using the virtual interference of protein activity by enriched regulon analysis (VIPER) algorithm 161”
InfluentialRosenberger, G., Li, W., Turunen, M. M., He, J., Subramaniam, P. S., Pampou, S., Griffin, A. T., Karan, C., Kerwin, P., Murray, D., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47957-3 · Cited by 24
“We use this de fi nition because we have shown that the mechanism of action of a drug in a tumor is well recapitulated in their OncoMatch-selected high-fi delity cell lines 43,44 .”
Self-citationFailli, M., Demir, S., Río-Álvarez, Á. D., Carrillo-Reixach, J., Royo, L., Domingo-Sàbat, M., Childs, M., Maibach, R., Alaggio, R., Czauderna, P. S., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000601 · Cited by 20
“The Califano lab [29] developed a sophisticated transcription-based oncology platform for predicting in vivo response to antineoplastics based on an ensemble of advanced computational approaches rooted in Information Theory.”
Method
Metadata
- Authors
- Mundi, P. S., Dela Cruz, F. S., Grunn, A., Diolaiti, D., Mauguen, A., Rainey, A. R., Guillan, K. C., Siddiquee, A., You, D., Realubit, R., Karan, C., Ortiz, M. V., Accordino, M., Mistretta, S., Brogan, F., Bruce, J. N., Caescu, C. I., Carvajal, R., Crew, K., Decastro, G., Heaney, M., Henick, B., Hershman, D., Hou, J., Iwamoto, F., Jurcic, J., Kiran, R. P., Kluger, M., Kreisl, T., Lamanna, N., Lassman, A., Lim, E., Manji, G. A., McKhann, G., McKiernan, J., Neugut, A., Olive, K., Rosenblat, T., Schwartz, G. K., Shu, C., Sisti, M., Tergas, A., Vattakalam, R., Welch, M., Wenske, S., Wright, J. D., Hibshoosh, H., Kalinsky, K., Aburi, M., Sims, P. A., Alvarez, M. J., Kung, A. L., & Califano, A.
- Affiliations
- Columbia University Irving Medical Center (US)
- Memorial Sloan Kettering Cancer Center (US)
- Emory University (US)
- Corresponding author
- Alvarez, Mariano J.
- Kung, Andrew L.
- Califano, Andrea
- ORCID
- Mundi, Prabhjot S.
- Dela Cruz, Filemon S.
- Grunn, Adina
- Diolaiti, Daniel
- Mauguen, Audrey
- Rainey, Allison R.
- Guillan, Kristina C.
- Siddiquee, Armaan
- You, Daoqi
- Realubit, Ronald
- Karan, Charles
- Ortiz, Michael V.
- Accordino, Melissa
- Mistretta, Suzanne
- Brogan, Frances
- Bruce, Jeffrey N.
- Caescu, Cristina I.
- Carvajal, Richard
- Crew, Katherine
- Decastro, Guarionex
- Heaney, Mark
- Henick, Brian
- Hershman, Dawn
- Hou, June
- Iwamoto, Fabio
- Jurcic, Joseph
- Kiran, Ravi P.
- Kluger, Michael
- Kreisl, Teri
- Lamanna, Nicole
- Lassman, Andrew
- Lim, Emerson
- Manji, Gulam A.
- McKhann, Guy
- McKiernan, James
- Neugut, Alfred
- Olive, Kenneth
- Rosenblat, Todd
- Schwartz, Gary K.
- Shu, Catherine
- Sisti, Michael
- Tergas, Ana
- Vattakalam, Reena
- Welch, Mary
- Wenske, Sven
- Wright, Jason D.
- Hibshoosh, Hanina
- Kalinsky, Kevin
- Aburi, Mahalaxmi
- Sims, Peter A.
- Alvarez, Mariano J.
- Kung, Andrew L.
- Califano, Andrea
- Venue
- Cancer Discovery
- Publisher
- openRxiv
- Published
- 2021-10-03
- Volume
- 13
- Issue
- 6
- Pages
- 1386-1407
- ISSN
- 2159-8274 (ISSN-L)
- PMC
- PMC10239356
- OpenAlex
- W4365997950
- Cited by
- 51
- References
- 85
- Citations by year
- 2026: 15 · 2025: 14 · 2024: 7 · 2023: 10 · 2022: 5
- FWCI
- 6.58
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Locations
- Cancer Discovery (publishedVersion)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- CureSearch for Children's Cancer
- Memorial Sloan-Kettering Cancer Center (CA008748, P30 CA008748)
- National Institutes of Health (1s10od021764-01, 1s10od032433-01a1, 1s10od012351-01, CA008748, CA013696)
- Irving Medical Center, Columbia University (P30 CA008748)
- NIH Office of the Director (S10OD021764, S10 OD012351)
- National Cancer Institute (S10OD021764, S10 OD012351, U54CA209997, CA008748, CA013696, OD012351, CA209997, U01CA217858, CA217858, OD021764, P30CA008748, U01CA272610, R35CA197745, P30CA013696)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- precision oncology, patient-derived xenografts, oncotarget, drug response prediction, basket trials, umbrella trials, disease control rate
- MeSH terms
- Antineoplastic Agents, Humans, Medical Oncology, Neoplasms, Precision Medicine, Transcriptome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.